デフォルト表紙
市場調査レポート
商品コード
1533897

HER2陰性乳がんの世界市場

HER2 - Negative Breast Cancer

出版日
ページ情報
英文 205 Pages
納期
即日から翌営業日
適宜更新あり
HER2陰性乳がんの世界市場
出版日: 2024年08月14日
発行: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
ページ情報: 英文 205 Pages
納期: 即日から翌営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

HER2陰性乳がんの世界市場は2030年までに215億米ドルに達する見込み

2023年に134億米ドルと推定されるHER2陰性乳がんの世界市場は、分析期間2023-2030年にCAGR 7.0％で成長し、2030年には215億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである放射線療法は、CAGR 6.4%を記録し、分析期間終了時には89億米ドルに達すると予測されます。ホルモン療法分野の成長率は、分析期間中CAGR 7.6％と推定されます。

米国市場は36億米ドルと推定、中国はCAGR 11.1％で成長予測

米国のHER2陰性乳がん市場は2023年に36億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに47億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは11.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.1%と6.9%と予測されています。欧州では、ドイツがCAGR 4.4%で成長すると予測されています。

世界のHER2陰性乳がん市場- 主要動向と促進要因のまとめ

HER2陰性乳がんとは、がん細胞の増殖を促進するタンパク質であるヒト上皮増殖因子受容体2（HER2）が陰性である乳がんのサブタイプを指します。全乳がんの約80％がHER2陰性であり、これはHER2タンパク質を過剰発現していないことを意味します。これらのがんは、ホルモン受容体（エストロゲン受容体およびプロゲステロン受容体）の有無によってさらに分類することができます。症例のかなりの割合を占めるホルモン受容体陽性HER2陰性乳がんは、エストロゲン受容体またはプロゲステロン受容体を標的とするホルモン療法によく反応する傾向があります。一方、HER2陰性でホルモン受容体を持たないトリプルネガティブ乳がん（TNBC）は、ホルモン療法やHER2標的療法に反応しないため、より攻撃的で治療が困難な場合が多いです。

HER2陰性乳がんの治療法は多様であり、現在進行中の研究と臨床の進歩により進化し続けています。ホルモン受容体陽性のHER2陰性乳がんに対しては、エストロゲンの作用を阻害し、がんの成長を遅らせるために、タモキシフェン、アロマターゼ阻害剤、CDK4/6阻害剤などの内分泌療法が一般的に使用されています。化学療法は、ホルモン受容体陽性乳がんとトリプルネガティブ乳がんの両方、特に進行期や転移性乳がんに対する治療の基本です。近年、免疫療法と標的療法がトリプルネガティブ乳がんに対する有望な選択肢として浮上してきました。免疫チェックポイント阻害剤であるペムブロリズマブや、オラパリブやタラゾパリブなどのPARP阻害剤のような治療薬は、特定の遺伝子プロファイルを持つ患者や標準治療が無効であった患者の予後を改善する有効性を示しています。さらに、ゲノム・プロファイリングを臨床に取り入れることで、より個別化された治療アプローチが可能になり、各患者のがん特有の遺伝子構成に合わせた治療ができるようになります。

HER2陰性乳がん治療薬市場の成長は、新たな治療法や患者の予後改善につながる研究開発の進展など、いくつかの要因によってもたらされます。世界の乳がん罹患率の増加に加え、意識の高まりや早期発見への取り組みにより、これらの治療法の対象となる患者層が拡大しています。診断ツールや遺伝子検査における技術の進歩は、がんのサブタイプをより正確に特定し、よりオーダーメイドの治療計画を可能にします。さらに、個別化医療へのシフトと、がんの進行に関与する特定の経路を標的とする新規薬剤の市場開拓が、市場成長の大きな促進要因となっています。画期的治療薬に対する規制当局の支援と迅速な承認プロセスは、革新的治療のイントロダクションをさらに促進します。製薬企業と研究機関の共同研究と相まって、がん研究への投資が拡大していることも、潜在的な新治療薬のパイプラインを促進し続けています。これらの要因が相まって、HER2陰性乳がん治療薬の市場は堅調かつダイナミックなものとなり、世界中の患者にとってより良い管理と生存率向上への希望がもたらされることになります。

調査対象企業の例（全61件）

  • Astrazeneca Pharmaceuticals LP
  • BeiGene
  • Beta Pharma
  • Celcuity
  • CytomX Therapeutics, Inc.
  • Daiichi Sankyo Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • Incyte Corporation
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Olema Oncology
  • Pfizer, Inc.
  • Prelude Therapeutics

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP27105

Global HER2 - Negative Breast Cancer Market to Reach US$21.5 Billion by 2030

The global market for HER2 - Negative Breast Cancer estimated at US$13.4 Billion in the year 2023, is expected to reach US$21.5 Billion by 2030, growing at a CAGR of 7.0% over the analysis period 2023-2030. Radiation Therapy, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$8.9 Billion by the end of the analysis period. Growth in the Hormonal Therapy segment is estimated at 7.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.6 Billion While China is Forecast to Grow at 11.1% CAGR

The HER2 - Negative Breast Cancer market in the U.S. is estimated at US$3.6 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$4.7 Billion by the year 2030 trailing a CAGR of 11.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global HER2 - Negative Breast Cancer Market - Key Trends and Drivers Summarized

HER2-negative breast cancer refers to a subtype of breast cancer that tests negative for human epidermal growth factor receptor 2 (HER2), a protein that promotes the growth of cancer cells. Approximately 80% of all breast cancers are HER2-negative, which means they do not overexpress the HER2 protein. These cancers can be further categorized based on the presence or absence of hormone receptors (estrogen and progesterone receptors). Hormone receptor-positive HER2-negative breast cancers, which account for a significant proportion of cases, tend to respond well to hormone therapies that target estrogen or progesterone receptors. On the other hand, triple-negative breast cancer (TNBC), which is both HER2-negative and lacks hormone receptors, is often more aggressive and difficult to treat, as it does not respond to hormonal or HER2-targeted therapies.

The treatment landscape for HER2-negative breast cancer is diverse and continues to evolve with ongoing research and clinical advancements. For hormone receptor-positive HER2-negative breast cancers, endocrine therapies such as tamoxifen, aromatase inhibitors, and CDK4/6 inhibitors are commonly used to block the effects of estrogen and slow cancer growth. Chemotherapy remains a cornerstone of treatment for both hormone receptor-positive and triple-negative breast cancers, especially in advanced stages or metastatic disease. In recent years, immunotherapy and targeted therapies have emerged as promising options for triple-negative breast cancer. Drugs like pembrolizumab, an immune checkpoint inhibitor, and PARP inhibitors such as olaparib and talazoparib have shown efficacy in improving outcomes for patients with specific genetic profiles or those who have failed standard treatments. Additionally, the integration of genomic profiling in clinical practice allows for more personalized treatment approaches, tailoring therapies to the unique genetic makeup of each patient's cancer.

The growth in the HER2-negative breast cancer therapeutics market is driven by several factors, including advancements in research and development that have led to new treatment modalities and improved patient outcomes. The increasing prevalence of breast cancer globally, coupled with heightened awareness and early detection efforts, has expanded the patient pool eligible for these therapies. Technological advancements in diagnostic tools and genetic testing enable more precise identification of cancer subtypes and more tailored treatment plans. Additionally, the shift towards personalized medicine and the development of novel drugs targeting specific pathways involved in cancer progression are significant drivers of market growth. Regulatory support and expedited approval processes for breakthrough therapies further facilitate the introduction of innovative treatments. The growing investment in oncology research, coupled with collaborations between pharmaceutical companies and research institutions, continues to fuel the pipeline of potential new therapies. These factors collectively ensure a robust and dynamic market for HER2-negative breast cancer therapeutics, providing hope for better management and improved survival rates for patients worldwide.

Select Competitors (Total 61 Featured) -

  • Astrazeneca Pharmaceuticals LP
  • BeiGene
  • Beta Pharma
  • Celcuity
  • CytomX Therapeutics, Inc.
  • Daiichi Sankyo Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • Incyte Corporation
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Olema Oncology
  • Pfizer, Inc.
  • Prelude Therapeutics

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • HER2 - Negative Breast Cancer - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Breast Cancer Prevalence Provides the Foundation for Growth in the Market
    • A Review of Advances in Chemotherapy and Hormonal Therapy for HER2-Negative Patients
    • Global Initiatives to Increase Awareness and Early Screening of Breast Cancer Drive Diagnosis Rates
    • Development of Targeted Therapies Offering New Hope for Patients
    • Anti-HER2 Therapies Grow in Popularity and Adoption
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World HER2 - Negative Breast Cancer Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for HER2 - Negative Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for HER2 - Negative Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Radiation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Radiation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Radiation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • HER2 - Negative Breast Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: USA 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Canada Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: Canada 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • JAPAN
    • HER2 - Negative Breast Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 23: Japan Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Japan Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Japan 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • CHINA
    • HER2 - Negative Breast Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: China Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: China 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • EUROPE
    • HER2 - Negative Breast Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 29: Europe Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for HER2 - Negative Breast Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for HER2 - Negative Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • FRANCE
    • HER2 - Negative Breast Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 35: France Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: France Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: France 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • GERMANY
    • HER2 - Negative Breast Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 38: Germany Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Germany Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Germany 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 41: Italy Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Italy Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Italy 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • HER2 - Negative Breast Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 44: UK Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: UK Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: UK 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 47: Spain Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Spain Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Spain 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 50: Russia Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Russia Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Russia 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Rest of Europe Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Rest of Europe 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • HER2 - Negative Breast Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for HER2 - Negative Breast Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for HER2 - Negative Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Asia-Pacific 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • HER2 - Negative Breast Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 62: Australia Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Australia Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Australia 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • INDIA
    • HER2 - Negative Breast Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 65: India Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: India Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: India 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 68: South Korea Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: South Korea Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: South Korea 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 71: Rest of Asia-Pacific Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Rest of Asia-Pacific Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Rest of Asia-Pacific 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • HER2 - Negative Breast Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for HER2 - Negative Breast Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for HER2 - Negative Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Latin America 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 80: Argentina Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Argentina Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Argentina 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 83: Brazil Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Brazil Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Brazil 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 86: Mexico Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Mexico Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Mexico 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 89: Rest of Latin America Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Latin America Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Latin America 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • HER2 - Negative Breast Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for HER2 - Negative Breast Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for HER2 - Negative Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Middle East 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 98: Iran Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Iran Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Iran 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 101: Israel Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Israel Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Israel 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 104: Saudi Arabia Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Saudi Arabia Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Saudi Arabia 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 107: UAE Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UAE Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: UAE 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 110: Rest of Middle East Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Rest of Middle East Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Rest of Middle East 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030
  • AFRICA
    • HER2 - Negative Breast Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 113: Africa Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Africa Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Africa 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030

IV. COMPETITION